Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) have been assigned an average recommendation of “Hold” from the nine analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $36.00.

A number of equities analysts have commented on ADMS shares. JMP Securities reissued an “outperform” rating and issued a $33.00 price objective (up from $29.00) on shares of Adamas Pharmaceuticals in a research note on Friday, August 25th. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub raised shares of Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 23rd. ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a research note on Friday, September 1st. They noted that the move was a valuation call.

Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 4.82% during mid-day trading on Friday, reaching $21.53. 1,175,386 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $18.00 and a 200-day moving average price of $17.19. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $22.58. The stock’s market capitalization is $484.73 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the previous year, the business earned ($0.78) earnings per share. The business’s quarterly revenue was down 90.9% on a year-over-year basis. Equities research analysts expect that Adamas Pharmaceuticals will post ($3.79) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Given Consensus Rating of “Hold” by Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/16/adamas-pharmaceuticals-inc-adms-given-consensus-rating-of-hold-by-analysts-2.html.

In related news, major shareholder Great Point Partners Llc sold 380,000 shares of Adamas Pharmaceuticals stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $17.08, for a total transaction of $6,490,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 731,041 shares of company stock valued at $12,476,149. 29.00% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Adamas Pharmaceuticals by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock valued at $12,537,000 after buying an additional 66,825 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Adamas Pharmaceuticals by 212.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after buying an additional 41,436 shares in the last quarter. Emerald Advisers Inc. PA lifted its holdings in Adamas Pharmaceuticals by 2.7% during the 2nd quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock valued at $9,317,000 after buying an additional 14,042 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Adamas Pharmaceuticals by 4.9% during the 1st quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock valued at $2,201,000 after buying an additional 5,920 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in Adamas Pharmaceuticals by 153.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after buying an additional 67,654 shares in the last quarter. Institutional investors own 69.24% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.